Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 15/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681229 | 0.91 | CACNA1H (0.38) | PDE2ACACNA1HEPHX2 | |
| SCHEMBL12188417 | 0.89 | PDE2A (0.48) | PDE2ACACNA1HEPHX2GPR139 | |
| SCHEMBL8223257 | 0.88 | PDE2A (0.50) | PDE2ACACNA1HEPHX2GPR139 | |
| SCHEMBL681325 | 0.88 | PDE2A (0.47) | PDE2ACACNA1HEPHX2GPR139 | |
| SCHEMBL680988 | 0.86 | SLC22A3 (0.44) | CACNA1H | |
| SCHEMBL681430 | 0.85 | MAPK1 (0.42) | CACNA1HEPHX2 | |
| SCHEMBL681015 | 0.83 | EPHX2 (0.48) | PDE2AEPHX2 | |
| SCHEMBL680927 | 0.82 | PDPK1 (0.44) | CACNA1H | |
| SCHEMBL680749 | 0.81 | PDE2A (0.41) | PDE2A | |
| SCHEMBL679630 | 0.81 | ALDH1A1 (0.46) | PDE2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | PDE2A 1813/4885CACNA1H 4866/4885EPHX2 2203/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | PDE2A 1813/4885CACNA1H 4866/4885EPHX2 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.